Abstract: Compounds of formula (I) are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved.

Abstract: Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids Compounds of the formula I are suitable for preparing pharmaceuticals for the treatment of disorders in the course of which is involved an increased activity of matrix-degrading metalloproteinases.

Abstract: Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids

Abstract: Compounds of the formula I are suitable for preparing pharmaceuticals for the treatment of disorders in the course of which is involved an increased activity of matrix-degrading metalloproteinases.

Abstract: Compounds of formula (I) 1

Abstract: Compounds of the formula (I): are suitable for the preparation of pharmaceuticals for prophylaxis and treatment of all those diseases where an increased concentration of interleukin-1&bgr; participates in their course, for example septic shock, leukemia, hepatitis, muscular degeneration, HIV infections or degenerative joint diseases (such as osteoarthrosis, spondylosis, chondrolysis following joint trauma or prolonged immobilization of joints following meniscus or patella injuries, or torn ligaments), diseases of the connective tissue (such as collagenosis, periodontal diseases, or wound-healing disturbances), and chronic diseases of the locomotor system (such as inflammatory or immunologically or metabolism-related acute and chronic arthritis, arthropathies, rheumatoid arthritis, myalgias and disturbances in bone metabolism).

Abstract: Compounds of formula (I) are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved.

Abstract: Compounds of formula (I) are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved

Abstract: Compounds of the formula I: stereoisomeric forms, and physiologically tolerable salts thereof are suitable for the production of pharmaceuticals for the therapy and prophylaxis of disorders involving matrix-degrading metalloproteinases.

Abstract: Compounds of the formula (I): 1

Abstract: Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids

Abstract: Compounds of the formula (I): are suitable for the preparation of pharmaceuticals for prophylaxis and treatment of all those diseases where an increased concentration of interleukin-1&bgr; participates in their course, for example septic shock, leukemia, hepatitis, muscular degeneration, HIV infections or degenerative joint diseases (such as osteoarthrosis, spondylosis, chondrolysis following joint trauma or prolonged immobilization of joints following meniscus or patella injuries, or torn ligaments), diseases of the connective tissue (such as collagenosis, periodontal diseases, or wound-healing disturbances), and chronic diseases of the locomotor system (such as inflammatory or immunologically or metabolism-related acute and chronic arthritis, arthropathies, rheumatoid arthritis, myalgias and disturbances in bone metabolism).

Abstract: Compounds of the formula I are suitable for preparing pharmaceuticals for the treatment of disorders in the course of which is involved an increased activity of matrix-degrading metalloproteinases.

Abstract: Compounds of the formula I: stereoisomeric forms, and physiologically tolerable salts thereof are suitable for the production of pharmaceuticals for the therapy and prophylaxis of disorders involving matrix-degrading metalloproteinases.

Abstract: Compounds of formula (I) ##STR1## are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved.

Abstract: Use of xanthine derivatives for the treatment of nerve damage following an interruption in blood circulation.The invention relates to the use of xanthine derivatives of the formula I ##STR1## in which R.sup.2 is a (C.sub.1 -C.sub.4)-alkyl group and at least one of the symbols R.sup.1 and R.sup.3 is a radical of the formula II or III ##STR2## in which A is CHOH, CO or dioxolane, R.sup.4 is a hydrogen atom or a (C.sub.1 -C.sub.4)-alkyl group and n is 0 to 5, and in which R.sup.5 and R.sup.6 are hydrogen atoms or (C.sub.1 -C.sub.4)-alkyl groups or, together with the nitrogen atom to which they are bonded, form a 5- to 7-membered ring, it being possible for one carbon atom to be replaced by an oxygen or nitrogen atom, m is 1 or 2 and the other radical R.sup.1 or R.sup.3, if appropriate, is a hydrogen atom, a (C.sub.1 -C.sub.6)-alkyl group or a (C.sub.3 -C.sub.

Abstract: The present invention relates to 2-cyano-3-mercaptocrotonamide derivatives, a process for their preparation, and their use the treatment of immune disorders, carcinomatous disorders, rejection reactions in transplantations and skin disorders or allergy.

Abstract: Phosphonoacetic acid derivatives and their use for treating degenerative joint disorders Compounds of the formula I ##STR1## are suitable for producing pharmaceuticals for the treatment and prophylaxis of degenerative joint disorders, of rheumatic disorders accompanied by cartilage breakdown, such as rheumatoid arthritis, joint trauma and chondrolysis as a consequence of prolonged immobilization of the joint, of inflammations, septic shock, disorders with impaired leukocyte adhesion, disorders caused by an elevated concentration of tumor necrosis factor alpha, such as cachexia or Crohn's disease.

Abstract: Novel substituted thiazoles of the formula I ##STR1## in which R.sup.1 is a saturated or unsaturated, straight-chain or branched C.sub.1 -C.sub.5 -alkyl group,R.sup.2 is a hydrogen atom or an alkyl radical having 1 to 3 carbon atoms,A is an intermediate chain of the formula--(CH.sub.2).sub.n --Y--CR.sup.3 R.sup.4 --; --CH.dbd.CR.sup.3 --(CH.sub.2).sub.m -- or --CH.dbd.N--O--(CH.sub.2).sub.n --whereY is a single bond, an oxygen or sulfur atom or a carbonyl group,R.sup.3 and R.sup.4 are identical or different and are a hydrogen atom or an alkyl radical having up to two carbon atoms, m is a number from 0 to 3 and n is a number from 1 to 4, andZ is a tetrazole or CN group, or a radical of the formula ##STR2## X is a hydroxyl group or a radical of the formula R.sup.5 O-- or R.sup.6 R.sup.7 N--, where R.sup.5 is a straight-chain or branched C.sub.1 -C.sub.4 -alkyl radical which is optionally substituted by hydroxyl, C.sub.1 -C.sub.3 -alkoxy or C.sub.1 -C.sub.3 -alkylamino,R.sup.6 and R.sup.

Abstract: Novel 5-(3-alkyl-5-tert.butyl-4-hydroxyphenyl)-2-amino-6H-1,3,4-thiadiazines of the general formula I ##STR1## in which R.sup.1 =C.sub.1 -C.sub.4 -alkyl,R.sup.2 =H or C.sub.1 -C.sub.3 -alkylR.sup.3 and R.sup.4 =independently of one another, optionally substituted and optionally O- or S-interrupted alkyl, alkenyl or alkynyl groups, it being possible for one of the two radicals to also be H,or R.sup.3 +R.sup.4 together with the nitrogen atom to which they are bound, may denote an optionally substituted 4- to 7-membered ring which optionally contains a further heteroatom (O, S or N),and the physiologically acceptable acid-addition salts thereof. The compounds are primarily suitable for prevention and treatment of inflammatory--in particular inflammatory rheumatic--disorders and/or pain.